Viekira Pak franchise
Author: Michael Haydock
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market. Viekira Pak is AbbVie’s first-generation interferon-free regimen, approved for the treatment of GT-1 chronic hepatitis C virus (HCV) infections within the US and five major EU markets (France, Germany, Italy, Spain, and the UK). The regimen contains a fixed-dose combination of paritaprevir, an NS3A and NS3/4A protease inhibitor boosted with ritonavir, and ombitasvir, an NS5A inhibitor. Dasabuvir, a non-nucleoside NS5B inhibitor, is also included in the regimen but is taken in a separate pill. Within the US, an extended release, once-daily fixed-dose combination of all four components is also available under the brand name Viekira XR. Within the EU, the components of AbbVie’s interferon-free regimen are marketed under the brand names Viekirax ([paritaprevir + ritonavir + ombitasvir]) and Exviera (dasabuvir). Within Japan, only the paritaprevir/ritonavir/ombitasvir fixed-dose combination is marketed, and is sold under the Viekirax brand name. In the US, the paritaprevir/ritonavir/ombitasvir fixed-dose combination is marketed under the brand name Technivie, and is approved for use in GT-4 patients only.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Viekira Pak franchise : Hepatitis C
11 Figure 1: Viekira Pak franchise for hepatitis C – SWOT analysis
LIST OF FIGURES
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of the Viekira Pak franchise for hepatitis C
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of the Viekira Pak franchise for hepatitis C
15 Figure 4: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country, 2017–26
17 Figure 5: Viekira XR sales for hepatitis C in the US, 2017–26
18 Figure 6: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Viekira Pak franchise drug profile
7 Table 2: Pivotal studies supporting approvals of the Viekira Pak franchise
16 Table 3: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country ($m), 2017–26
17 Table 4: Viekira XR sales for hepatitis C in the US ($m), 2017–26
19 Table 5: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Daklinza 
Sign up to the